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Abstract
A number of histone methyltransferases have been identified and biochemically characterized, but the pathologic roles of
their dysfunction in human diseases like cancer are not well understood. Here, we demonstrate that Wolf-Hirschhorn syn-
drome candidate 1 (WHSC1) plays important roles in human carcinogenesis. Transcriptional levels of this gene are signif-
icantly elevated in various types of cancer including bladder and lung cancers. Immunohistochemical analysis using a
number of clinical tissues confirmed significant up-regulation of WHSC1 expression in bladder and lung cancer cells at
the protein level. Treatment of cancer cell lines with small interfering RNA targeting WHSC1 significantly knocked down
its expression and resulted in the suppression of proliferation. Cell cycle analysis by flow cytometry indicated that knock-
down of WHSC1 decreased the cell population of cancer cells at the S phase while increasing that at the G2/M phase.
WHSC1 interacts with some proteins related to the WNT pathway including β-catenin and transcriptionally regulates
CCND1, the target gene of the β-catenin/Tcf-4 complex, through histoneH3 at lysine 36 trimethylation. This is a novelmech-
anism for WNT pathway dysregulation in human carcinogenesis, mediated by the epigenetic regulation of histone H3. Be-
cause expression levels of WHSC1 are significantly low in most normal tissue types, it should be feasible to develop
specific and selective inhibitors targeting the enzyme as antitumor agents that have a minimal risk of adverse reaction.
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Introduction
The N-terminal histone tails are subjected to posttranslational modi-
fications, including methylation, acetylation, and phosphorylation,
generating an extensive repertoire of chromatin structures [1,2]. We
previously reported that SMYD3, a histone lysine methyltransferase,
stimulates proliferation of cells and plays an important role in human
carcinogenesis through its methyltransferase activity [3,4]. With the
exception of Dot1/DOT1L, all histone lysine methyltransferases
(HKMTs) contain a SET domain of approximately 130 amino
acids [5]. The SET domain was originally identified as a domain shared
by three Drosophila proteins involved in epigenetic processes: the sup-
pressor of position-effect variegation (Su[var]3-9), an enhancer of the
eye color mutant zeste that belongs to the PcG proteins (E [Z ]), and the
homeobox gene regulator trithorax (TRX) [6]. Mammalian homologs
of Drosophila Su(var)3-9, Suv39h1 and Suv39h2, were the first ones
characterized as HKMTs and specifically methylate histone H3 at
lysine 9 (H3K9) [7]. So far, nearly 40 HKMTs or potential HKMTs
containing the SET domain have been identified, and some of them
are shown to methylate lysine residues at codons 4, 9, 27, or 36 of his-
tone H3 and lysine 20 of histone H4. The HKMTs can be classified
into several different families according to sequence similarities within
their SET domain and within the adjacent sequences, as well as other
structural features such as the presence of other defined protein do-
mains [5]. While our knowledge of the physiological functions of his-
tone methyltransferases is growing, their involvement in human
disease remains largely unclear.
To investigate possible roles of HKMTs in human carcinogenesis,
we examined the expression profiles of human HKMTs in clinical tis-
sues and found that expression levels of WHSC1 were significantly
upregulated, compared with their corresponding normal tissues, in
various types of cancer. WHSC1, also known as NSD2 or MMSET,
was identified as a candidate gene for Wolf-Hirschhorn syndrome
(WHS) [8]. The WHSC1 protein contains AWS, SET, and PostSET
domains that are highly conserved in yeast H3K36-specific methyl-
transferase Set2, and mouse Whsc1 was recently reported to govern
H3K36me3 distribution along euchromatin by associating with the
cell type–specific transcription factors Sall1, Sall4, and Nanog in em-
bryonic stem cells [9].WHSC1 is composed of 25 exons and undergoes
complex alternative splicing [8]. A transcript initiating in the middle of
WHSC1, which encodes the C-terminal half of the WHSC1 protein,
was previously isolated through its ability to bind to the response ele-
ment II of the interleukin 5 (IL-5) promoter and to repress its tran-
scription [10]. This supports a role for WHSC1 in transcription.
Through translocations t(4;14) (p16.3;q32.3), WHSC1 is indicated
to be involved in multiple myeloma [8,11–15], playing a critical role
in the cell cycle regulation of the myeloma cells [12]. Although it is also
possible that WHSC1 is involved in some solid tumors [16,17], a de-
tailedmechanism describing how deregulation ofWHSC1 contributes
to human carcinogenesis is still uncertain. Here, we investigate the
involvement of WHSC1 in human cancers and implicate it as a can-
didate therapeutic target for various types of cancer.
Materials and Methods
Bladder Tissue Samples and RNA Preparation
Bladder tissue samples and RNA preparation were described previ-
ously [18]. Briefly, 120 surgical specimens of primary urothelial carci-
noma were collected, either at cystectomy or at transurethral resection
of bladder tumor (TURBT), and snap frozen in liquid nitrogen. Twenty-
two specimens of normal bladder urothelial tissue were collected from
areas of macroscopically normal bladder urothelium in patients with
no evidence of malignancy. Vimentin is primarily expressed in mes-
enchymally derived cells, and this was used as a stromal marker.
Uroplakin is a marker of urothelial differentiation and is preserved
in up to 90% of epithelially derived tumors [19]. Use of tissues for this
study was approved by Cambridgeshire Local Research Ethics Com-
mittee (Ref 03/018).
Lung Tissue Samples for Tissue Microarray
Primary non–small cell lung cancer (NSCLC) tissue samples as well
as their corresponding normal tissues adjacent to resection margins
from patients having no anticancer treatment before tumor resection
had been obtained earlier with informed consent [20–22]. All tumors
were staged based on the pathologic tumor-node-metastasis classifi-
cation of the International Union Against Cancer. Formalin-fixed pri-
mary lung tumors and adjacent normal lung tissue samples used for
immunostaining on tissuemicroarrays had been obtained from328 pa-
tients undergoing curative surgery at Saitama Cancer Center (Saitama,
Japan) [23,24]. To be eligible for this study, tumor samples were se-
lected from patients who fulfilled all of the following criteria: 1) pa-
tients with primary NSCLC with a histologically confirmed stage
(only pT1 to pT3, pN0 to pN2, and pM0); 2) patients who underwent
curative surgery but did not receive any preoperative treatment; 3)
among them, NSCLC patients with positive lymph node metastasis
(pN1, pN2) were treated with platinum-based adjuvant chemothera-
pies after surgical resection, whereas patients with pN0 did not receive
adjuvant chemotherapies; and 4) patients whose clinical follow-up data
were available. This study and the use of all clinical materials men-
tioned were approved by individual institutional ethics committees.
Cell Culture
All cell lines were grown in monolayers in appropriate media:
Dulbecco modified Eagle medium for EJ28, RERF-LC-AI, HepG2,
and 293T cells; Eagle minimal essential medium for IMR-90, 253J,
253J-BV, HT1197, HT1376, J82, SCaBER, UMUC3, and SBC5
cells; Leibovitz L-15 for SW780 and SW480 cells;McCoy 5Amedium
for RT4, T24, and HCT116 cells; RPMI 1640 medium for 5637,
A549, H2170, ACC-LC-319, and SNU475 cells supplemented with
10% fetal bovine serum and 1% antibiotic/antimycotic solution
(Sigma-Aldrich, St Louis, MO). LoVo cells were cultured in Ham
F-12 medium supplemented with 20% fetal bovine serum and 1%
antibiotic/antimycotic solution. Small airway epithelial cells (SAECs)
were maintained in small airway epithelial cell basal medium sup-
plemented with 52 μg/ml bovine pituitary extract, 0.5 ng/ml human
recombinant epidermal growth factor (EGF), 0.5 μg/ml hydrocortisone,
0.5 μg/ml epinephrine, 10 μg/ml transferrin, 5 μg/ml insulin, 0.1 ng/ml
retinoic acid, 6.5 ng/ml triiodothyronine, 50 μg/ml gentamicin/
amphotericin-B (GA-1000; Lonza, Basel, Switzerland), and 50 μg/ml
fatty acid–free bovine serum albumin. All cells were maintained at
37°C in humid air with 5% CO2 condition (IMR-90, SAEC, 5637,
253J, 253J-BV, EJ28, HT1197, HT1376, J82, RT4, SCaBER, T24,
UMUC3, A549, H2170, ACC-LC-319, RERF-LC-AI, SBC5, 293T,
HepG2, SNU475, Huh7, and LoVo) or without CO2 (SW780 and
SW480). Cells were transfected with FuGENE6 (Roche Applied Sci-
ence, Penzberg, Germany) according to the manufacturer’s protocols.
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Expression Profiling in Cancer Using Complementary
DNA Microarrays
We established a genome-wide complementary DNA (cDNA) micro-
array with 36,864 cDNA selected from the UniGene database of the
National Center for Biotechnology Information. This microarray sys-
tem was constructed essentially as described previously [21,25,26].
Briefly, the cDNAwere amplified by reverse transcription–polymerase
chain reaction (RT-PCR) using poly (A)+ RNAs isolated from various
human organs as templates; the lengths of the amplicons ranged from
200 to 1100 bp, without any repetitive or poly (A) sequences. Many
types of tumor and corresponding nonneoplastic tissues were prepared
in 8-μm sections, as described previously [25]. A total of 30,000 to
40,000 cancer or noncancerous cells were collected selectively using
the EZ cut system (SL Microtest GmbH, Jena, Germany) according
to the manufacturer’s protocol. Extraction of total RNA, T7-based
amplification, and labeling of probes were performed as described pre-
viously [25]. A measure of 2.5-μg aliquots of twice-amplified RNA
(aRNA) from each cancerous and noncancerous tissue was then la-
beled, respectively, with Cy3-dCTP or Cy5-dCTP.
Quantitative Real-time PCR
We prepared 120 bladder cancer and 22 normal bladder tissues in
Addenbrooke’s Hospital, Cambridge (previously mentioned). For
quantitative RT-PCRs, specific primers for all human GAPDH (house-
keeping gene), SDH (housekeeping gene), and WHSC1 were designed
(Table W1). PCRs were performed using the LightCycler 480 System
(Roche Applied Science) following the manufacturer’s protocol.
Immunohistochemical Staining
The expression patterns ofWHSC1 in bladder and lung tumors and
normal human tissues were examined by immunohistochemistry as de-
scribed previously [27–29]. Briefly, slides of paraffin-embedded blad-
der tumor specimens and normal human tissues were processed under
high pressure (125°C, 30 seconds) in antigen-retrieval solution, high
pH 9 (S2367; Dako, Carpinteria, CA), treated with peroxidase block-
ing reagent, and then treated with protein blocking reagent (Dako).
Tissue sections were incubated with the rabbit anti-WHSC1 polyclonal
antibody (HPA015801, 1:80; Sigma-Aldrich) followed by HRP-
conjugated secondary antibody (Dako). Antigen was visualized with
substrate chromogen (Dako liquid DAB chromogen; Dako). Finally,
tissue specimens were stained with Mayer hematoxylin (Hematoxylin
QS; Vector Laboratories, Burlingame, CA) to discriminate the nucleus
from the cytoplasm. Three independent investigators semiquantita-
tively assessed WHSC1 positivity without prior knowledge of clinico-
pathologic data. Because the intensity of staining within each tumor
tissue core wasmostly homogeneous, the intensity ofWHSC1 staining
was semiquantitatively evaluated using the following criteria: negative
(no appreciable staining in tumor cells), low or moderate (brown stain-
ing appreciable in 5%-50% of the nucleus of tumor cells), and high
(brown staining appreciable in >50% of the nucleus of tumor cells).
Cases were accepted as positive only if all reviewers independently de-
fined them as such.
Small Interfering RNA Transfection
Small interfering RNA (siRNA) oligonucleotide duplexes were
purchased from Sigma-Aldrich for targeting the humanWHSC1 tran-
scripts. siEGFP and siNegative control (siNC), which is a mixture of
three different oligonucleotide duplexes, were used as control siRNA.
The siRNA sequences are described in Table W2. siRNA duplexes
(100 nM final concentration) were transfected into bladder and lung
cancer cell lines with Lipofectamine 2000 (Life Technologies, Carlsbad,
CA) for 72 hours, and cell viability was examined using the Cell Count-
ing Kit-8 (Dojindo, Kumamoto, Japan).
Coupled Cell Cycle and Cell Proliferation Assay
A 5′-bromo-2′-deoxyuridine (BrdU) flow kit (BD Pharmingen, San
Diego, CA) was used to determine the cell cycle kinetics and to mea-
sure the incorporation of BrdU into DNA of proliferating cells. The
assay was performed according to the manufacturer’s protocol. Briefly,
cells (2 × 105 per well) were seeded overnight in six-well tissue culture
plates and treated with an optimized concentration of siRNA in me-
dium containing 10% fetal bovine serum for 72 hours, followed by
addition of 10 μMBrdU, and incubations continued for an additional
30 minutes. Both floating and adherent cells were pooled from tripli-
cate wells per treatment point, fixed in a solution containing parafor-
maldehyde and the detergent saponin, and incubated for 1 hour with
DNase at 37°C (30 μg per sample). Fluorescein isothiocyanate–
conjugated anti-BrdU antibody (1:50 dilution in wash buffer; BD
Pharmingen) was added, and incubation continued for 20 minutes
at room temperature. Cells were washed in wash buffer, and total
DNA was stained with 7-amino-actinomycin D (7-AAD; 20 μl per
sample), followed by flow cytometric analysis using FACScan
(Beckman Coulter, Brea, CA), and total DNA content (7-AAD) was
determined CXP Analysis Software Ver. 2.2 (Beckman Coulter).
Immunocytochemistry
Cells were fixed with PBS (−) containing 4% paraformaldehyde for
20 minutes, and rendered permeable with PBS (−) containing 0.1%
Triton X-100 at room temperature for 2 minutes. Subsequently, the
cells were covered with PBS (−) containing 3% bovine serum albumin
for 1 hour at room temperature to block nonspecific hybridization and
then were incubated with a rabbit anti-FLAG antibody (F7425; Sigma-
Aldrich) at a 1:1000 dilution ratio, a rabbit anti-WHSC1 anti-
body (HPA015801) at a 1:100 dilution ratio, a mouse anti–β-catenin
antibody (610153; BD Biosciences, Palo Alto, CA) at a 1:500 dilu-
tion ratio, and an anti–active β-catenin antibody (05-655; Millipore,
Billerica, MA) at a 1:200 dilution ratio. After washing with PBS (−),
cells were stained by an Alexa Fluor 488–conjugated anti-rabbit sec-
ondary antibody (Life Technologies) or an Alexa Fluor 594–conjugated
anti-mouse secondary antibody (Life Technologies) at a 1:500 dilu-
tion ratio. Nuclei were counterstained with 4′,6′-diamidine-2′-
phenylindole dihydrochloride (DAPI). Fluorescent images were
obtained under a TCS SP2 AOBS microscope (Leica Microsystems,
Wetzlar, Germany).
Microarray Hybridization and Statistical Analysis for the
Clarification of Downstream Genes
Microarray analysis to identify downstream genes was done as de-
scribed previously [30–32]. Purified total RNA was labeled and hy-
bridized onto Affymetrix GeneChip U133 Plus 2.0 oligonucleotide
arrays (Affymetrix, Santa Clara, CA) according to the manufacturer’s
instructions. Probe signal intensities were normalized by Robust
Multichip Average and Quantile (using R and Bioconductor).
Immunoprecipitation
293T cells were seeded at a density of 5 × 105 cells on a 100-mm
dish. The next day, cells were transfected with p3×FLAG-CMV10
(mock) or p3×FLAG-CMV10-WHSC1. After 48 hours, transfected
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293T cells were washed with PBS and lysed in CelLytic M Cell Lysis
Reagent (Sigma-Aldrich) containing complete protease inhibitor cock-
tail (Roche Applied Science). Five hundred micrograms of whole-cell
extract was preincubated overnight with anti-HA agarose (Sigma-
Aldrich) to prevent nonspecific bindings at 4°C and then incubated
with anti-FLAG M2 agarose (Sigma-Aldrich) for 1 hour at 4°C. After
the beads were washed three times with 1 ml of Tris-buffered saline
buffer (pH 7.6), the FLAG-tagged proteins bound to the beads were
eluted by 3× FLAG peptide (Sigma-Aldrich) and boiled for 5 min-
utes in SDS sample buffer. Samples were then subjected to SDS–
polyacrylamide gel and detected by silver staining or Western blot.
With regard to mass spectrometry analysis, we submitted the samples
to Shimadzu Biotech (Kyoto, Japan).
In Vitro Binding Assay
The in vitro binding assay was described previously [33]. Briefly, the
C-terminal region of His-conjugated WHSC1 (residues 782-1365)
and GST-conjugated full-length β-catenin was mixed in TBS buffer
(pH 7.6). After binding with TALONMetal Affinity Resin (Clontech,
Mountain View, CA) for 1 hour, samples were washed three times with
TBS buffer and boiled in sample buffer for subjecting to SDS-PAGE.
Proteins were detected byCoomassie brilliant blue staining andWestern
blot analysis using anti-GST (sc-138; Santa Cruz Biotechnology, Santa
Cruz, CA) and anti-His (631212; Clontech) antibodies.
Chromatin Immunoprecipitation Assay
Chromatin immunoprecipitation (ChIP) assays were performed us-
ing the ChIP Assay Kit fromMillipore according to the manufacturer’s
protocol. Briefly, the fragment of WHSC1 and chromatin complexes
was immunoprecipitatedwith anti-FLAG antibody 48 hours after trans-
fection with pCAGGS-n3FC (mock), pCAGGS-n3FC-WHSC1wt
(WHSC1wt, isoform1), or pCAGGS-n3FC-WHSC1ΔSET
(WHSC1ΔSET) vector in 293T cells. After the DNA fragments bound
to WHSC1wt or WHSC1ΔSET were eluted, an aliquot was subjected
to quantitative real-time PCR. Protein A agarose/Salmon Sperm DNA
(16-157; Millipore) was used as a control. Primer sequences are shown
in Table W3.
Luciferase Assays for TOPFLASH and
FOPFLASH Reporter Activities
The luciferase assays were performed using Dual-Luciferase Reporter
Assay System (Promega, Fitchburg, WI) according to the manufac-
turer’s protocol. 293T cells were cultured on 24-well microplates
and cotransfected with pCAGGS-n3FC (mock), pCAGGS-n3FC-
WHSC1wt (WHSC1wt, isoform1), pCAGGS-n3FC-WHSC1ΔSET
(WHSC1ΔSET)TOPFLASH, FOPFLASH, and pRL-TK, which was
used as an internal control, vectors in a suitable combination. Cells
were lysed 48 hours after transfection for analysis, and luciferase activ-
ity was measured with a luminometer (Berthold Technologies, Bad
Wildbad, Germany).
Results
Overexpression of WHSC1 in Clinical Cancer Tissues
By examining the levels of histone lysine methyltransferase gene ex-
pressions in a small subset of British clinical bladder cancer samples, we
detected significant overexpression of WHSC1 in the cancer tissues,
compared with normal tissue types (Figure 1A). We also found that,
in bladder cancer cell lines,WHSC1 expression was significantly higher
than that in normal cell lines (Figure 1B). We then analyzed 120 blad-
der cancer samples and 22 normal control samples (British) and ob-
served, here also, a significant elevation of WHSC1 expression levels
in tumor cells compared with normal cells (both P < .0001, Mann-
Whitney U test). Subclassification of tumors according to tumor
grade, metastasis status, sex, recurrence status, and smoking history
identified no significant correlation with WHSC1 expression levels
(Table W4). In addition, our previous microarray expression analysis
of a large number of clinical samples [21,26,34,35] indicated that
WHSC1 expression was significantly upregulated in various cancer
types (Figure 1C and Table W5).
Up-regulation of WHSC1 Protein in a Number
of Bladder and Lung Tumor Tissues
To evaluate protein expression of WHSC1 in bladder tissues, we
performed immunohistochemistry using an anti-WHSC1 antibody.
The specificity of the antibody was validated by Western blot analysis
(Figure W1, A and B), and WHSC1 protein expression in cancer cell
lines was significantly higher than that in the normal fibroblast cell
IMR-90. Immunohistochemical analysis of tissue sections showed that
WHSC1 staining is strong in the nucleus of malignant cells but weak
or absent staining in nonneoplastic tissues (Figure W2A). Next, we
analyzed protein expression levels of WHSC1 in bladder tissues using a
tissue microarray of 29 bladder tissue sections (Figure 2 and Table W6)
and detected its strong staining in 17 cases, with weak or moderate
staining observed in 9 cases. However, we found no significant relation-
ship between WHSC1 protein expression levels and clinicopathologic
characteristics, consistent with our real-time PCR results.
Because our cDNA microarray data showed elevated expression of
WHSC1 in lung cancer tissues, we conducted quantitative real-time
PCR on a number of clinical NSCLC tissues. By this method also, ex-
pression levels ofWHSC1 in lung cancer tissues are significantly higher
than in various normal tissue types (Figure 3, A and B). Elevated
expression of WHSC1 was also observed in lung cancer cell lines
(Figure 3C ), so we examined expression levels of WHSC1 in vari-
ous histologic types of lung tumor tissues by tissue microarray
(Figure W2B and Table W7). Of 62 lung tumor tissue sections exam-
ined, we observed strong staining in 20 cases and weak or moderate
staining in 26 cases with no detectable staining in the remainder. To
examine the association ofWHSC1 expression with clinical outcomes,
we performed immunohistochemistry on tumor tissue microarrays
containing 328 archival NSCLC cases (Figure 3D). WHSC1 stained
positively in 174 cases (53.05%) and negatively in 154 cases (46.95%;
Figure 3E ). Meanwhile, no significant statistical significance was
observed between WHSC1 positivity and any patient characteristics
(Table W8). Univariate analysis of association between prognosis
and WHSC1 expression demonstrated no statistical significance (P =
.8629 by log-rank test; FigureW3 and TableW9). These results reveal
that WHSC1 is frequently overexpressed in lung cancer regardless of
clinical characteristics and that it does not serve as a prognostic marker.
WHSC1 Regulates the Growth of Cancer Cells
To examine whether elevated expression of WHSC1 plays a critical
role in the proliferation of cancer cells, we prepared siRNA oligonucle-
otide duplexes, which specifically suppressed the expression of
WHSC1 (siWHSC1 #1 and #2; Figure 4A), and transfected them into
cancer cells. Cell-counting assays (Figure 4B) showed that transfection
of siWHSC1 significantly suppressed cancer cell growth, compared
with those with siEGFP or siNC. This result was obtained with two
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independent siWHSCs in four different cell lines: two bladder and two
lung cancer cell lines. Staining with BrdU and 7-AAD was performed
to analyze the detailed cell cycle status of cancer cells. We confirmed
that, after the knockdown of WHSC1, the proportion of cancer cells
at the S phase was significantly reduced and that in the G2/M phase
was increased (Figure 4C ). This implies that WHSC1 plays an impor-
tant role in cell cycle regulation in cancer cells.
WHSC1 Contributes to Carcinogenesis through
Regulation of the WNT Pathway
Immunoprecipitation–mass spectrometry analysis revealed
IQGAP1 and TIAM1 as candidate interacting partners with WHSC1
(Figure 5A), and we confirmed these interactions by coimmunopre-
cipitation using specific antibodies (Figure 5B). IQGAP1 and TIAM1
are both involved in the WNT signaling pathway, through interaction
with β-catenin protein [36,37], so we considered the possibility that
WHSC1 could interact with β-catenin and confirmed these interac-
tions (Figure 5, B and C ). Interestingly, immunoprecipitation analysis
after fractionation of nuclear/cytoplasmic material showed that the
interaction between WHSC1 and β-catenin was observed predomi-
nantly in the nuclear fraction (data not shown). In addition, we dem-
onstrated direct binding between recombinant His-conjugated
C-terminal region of WHSC1 and GST-conjugated full-length
β-catenin in vitro, suggesting that these proteins may bind each other
Figure 1. Elevated WHSC1 expressions in human cancers. (A) Expression levels of WHSC1 in human clinical tissues analyzed by quan-
titative real-time PCR. Various types of normal tissue and nine bladder cancer tissue samples were analyzed, and values are relative to
the brain. (B) Expression levels ofWHSC1 in cell lines analyzed by quantitative real-time PCR. A total of 2 normal cell lines and 12 bladder
cancer cell lines were used for the analysis, and values are relative to IMR-90. (C) Comparison of WHSC1 expression between normal
and tumor tissues in bladder cancer, breast cancer, prostate cancer, renal cancer, lung cancer (SCLC), and pancreas cancer. Signal
intensity of each sample was analyzed by cDNA microarray, and the result is shown by box-whisker plot (median, 50% boxed).
Mann-Whitney U test was used for the statistical analysis.
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directly (Figure 5D). Furthermore, we confirmed colocalization of
endogenous WHSC1 and β-catenin proteins in the nucleus, using
specific antibodies (Figure 5E ), indicating that theymay work together
in nuclei.
Using the Gene Ontology database, we performed a signal pathway
analysis to suggest downstream candidates (Materials and Methods;
Table W10). This indicated that WHSC1 might indeed regulate
the WNT signaling pathway. Deregulation of the WNT signaling
pathway has been frequently observed in colorectal cancer (CRC);
therefore, we examined expression profiles ofWHSC1 in CRC.Quan-
titative real-time PCR showed thatWHSC1 expression was elevated in
CRC cell lines (Figure W4A). In addition, tissue microarray immuno-
histochemical analysis of 68 colorectal adenocarcinoma tissue samples
demonstrated that WHSC1 was expressed in 78.4% of cancer tissues
(Figure W4, B and C ). This result implies that deregulation of
WHSC1 may also play an important role in colorectal carcinogenesis.
To clarify the details of the functional relationship between
WHSC1 and the WNT/β-catenin pathway, we examined the effect
of WHSC1 on the transcriptional activity of the β-catenin/Tcf-4 com-
plex. CCND1, an established downstream target of the β-catenin/
Tcf-4 complex, showed significantly reduced expression levels after
treatment with siWHSC1 by microarray, and this result was verified
by real-time PCR analysis (Figure 6A). We next performed ChIP anal-
ysis using five different primers targeting promoter regions of CCND1
gene. As shown in Figure 6B, both wild-type and enzyme-dead
WHSC1 bound each region, with particularly strong association at a
location near the transcriptional start site (Figure 6B). Enzyme-dead
WHSC1 (WHSC1ΔSET) showed a weaker association than wild-type
WHSC1 (WHSC1wt). Interestingly, histone H3K36me3 levels in the
promoter region of CCND1 gene were significantly increased after
transfection with wild-type WHSC1, whereas no elevation was ob-
served in the case of WHSC1ΔSET transfection. H3K36me3 status
was likely to correlate with the status of wild-type WHSC1 accumu-
lation. To analyze the specificity of this phenomenon, we performed
ChIP analysis using two additional primer sets, one targeting a region
5-kb downstream of the CCND1 transcription start site (TSS) and the
other, the CDK6 TSS region (Figure W5A). In these regions, neither
accumulation ofWHSC1 nor significant changes of H3K36 trimethyla-
tion status were observed (Figure W5, B and C ). This confirms that
WHSC1 can specifically associate with the promoter and TSS regions
of CCND1 and enhance trimethylation of histone H3 lysine 36 in that
area. Furthermore, overexpression of wild-type WHSC1 significantly
enhanced TOPFLASH reporter activity (Figure 6C), whereas enzyme-
dead WHSC1 resulted in TOPFLASH inactivity, indicating that
Figure 2. Tissue microarray images of bladder tissues stained by standard immunohistochemistry for protein expression of WHSC1.
Clinical information for each section is represented above histologic pictures. All tissue samples were purchased from BioChain
(Hayward, CA). Original magnification, ×400.
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WHSC1 can positively regulate β-catenin/Tcf-4 activity. These results
show that WHSC1 may regulate the WNT signaling pathway through
interaction with β-catenin. This may be one of themechanisms by which
WHSC1 contributes to human carcinogenesis.
Discussion
The wingless/int (WNT) signaling pathway regulates cellular prolifer-
ation and differentiation in vertebrates and invertebrates. β-Catenin is
a doubly functional molecule in the WNT signaling pathway and the
E-cadherin–catenin complex. When accumulated in the nucleus,
β-catenin loses its function as a cell-adhesion molecule and activates
the WNT signaling pathway, switching on transcription of target
genes including CCND1. It has been reported that dysregulation of
theWnt signaling pathway is involved inmany human cancers, includ-
ing bladder and lung cancers [38–42]. Mutations that promote consti-
tutive activation of the Wnt signaling pathway lead to cancer. The
best-known example is familial adenomatous polyposis, an autosomal,
dominantly inherited disease in which patients display polyps in the
colon and rectum. This disease is caused most frequently by trunca-
tions in APC [43] that promote aberrant activation of the Wnt path-
way leading to adenomatous lesions due to increased cell proliferation.
Mutations in β-catenin have also been found in sporadic colon can-
cers [44]. On the contrary, although the dysregulation of WNT sig-
naling in various types of cancer has been implied [45,46], such
mutations seem to be rare in a number of cancers including bladder
and lung carcinomas [38,47,48]. These data indicate that several
other factors yet unknown must also regulate the Wnt pathway in
human carcinogenesis.
In this study, we found that WHSC1 may interact with β-catenin
in the nucleus and, together, promote trimethylation of histone H3
at lysine 36 (H3-K36) in the promoter region of CCND1 (Figure 6D).
Generally, methylated H3-K36 is enriched in regions of active tran-
scription [49], and this has been linked to transcriptional elongation
[50] and alternative splicing [51]. In AML, the recurring t(5;11)(q35;
Figure 3. Elevated WHSC1 expression in lung cancer. (A) Expression levels ofWHSC1 in human clinical tissues analyzed by quantitative
real-time PCR. A total of 14 normal tissues and 17 NSCLC tissues (ADC 10 cases and SCC 7 cases) were used for the analysis. Mes-
senger RNA (mRNA) expression levels were normalized by GAPDH, and values are relative to the brain. ADC indicates adenocarcinoma;
SCC, squamous cell carcinoma. (B) Quantitative real-time PCR analysis of WHSC1 expression among 13 normal tissues (brain, breast
colon, esophagus, eye, heart, liver, pancreas, rectum, spleen, stomach, lung, and pancreas), 10 NSCLC-ADC, and 7 NSCLC-SCC tissue
samples. Statistical analysis was done using Kruskal-Wallis test, P = .0001; Student’s t test, *P< .05, **P < .0001. (C) Expression levels
of WHSC1 in cell lines analyzed by quantitative real-time PCR. Two normal cell lines and five lung cancer cell lines were used for the
analysis. mRNA expression levels were normalized by GAPDH, and values are relative to IMR-90. (D) Representative cases for positive or
negative WHSC1 expression in lung cancer tissues and a normal lung tissue. Original magnifications, ×100 and ×200. (E) Positive ratio
of WHSC1 in 328 lung tumor tissues.
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p15.5) translocation fuses NSD1 (a WHSC1 gene family member) to
nucleoporin 98 (NUP98) [52]. NUP98-NSD1 was shown to induce
AML in vivo and sustain self-renewal of myeloid stem cells in vitro
[53]. The NUP98-NSD1 complex binds genomic elements adjacent
to HoxA7 and HoxA9 and maintains H3-K36 trimethylation, pre-
venting transcriptional repression of the Hox-A locus. Inactivation of
the methyltransferase activity is achieved either by deletion of the
NUP98 FG-repeat domain or mutations in NSD1, preventing both
Hox-A gene activation and myeloid progenitor immortalization.
Therefore, NSD1-dependent H3-K36 methylation is likely to play a
critical role in tumorigenesis. In the same way, WHSC1 cooperatively
enforces the transcriptional activity of β-catenin by maintaining
H3-K36 trimethylation. This implies that WHSC1-dependent
H3-K36 methylation may promote tumorigenesis in a synergistic
manner together with β-catenin. We thus present a novel mechanism
for WNT pathway dysregulation in human carcinogenesis, through
epigenetic regulation.
Meanwhile, there are other reports of WHSC1 functioning as a
transcriptional repressor through regulation of histone methylation
[14,15].Methylation by SET domains differs subtly betweenWHSC1
gene family members (the family includes NSD1 and WHSC1L1).
NSD1 was initially shown to methylate both H3 and H4 histones,
and more recently, its specificity has been narrowed down to histone
H3 [53]. Likewise,WHSC1 (also calledMMSET) was able to methylate
Figure 4. Involvement of WHSC1 in the growth of bladder and lung cancer cells. (A) Quantitative real-time PCR showing suppression of
endogenous expression ofWHSC1 by two WHSC1-specific siRNA (siWHSC1#1 and #2) in SW780 cells. siEGFP and siNC were used as
controls. mRNA expression levels were normalized by GAPDH and SDH expressions, and values are relative to siEGFP (siEGFP = 1).
Results are the mean ± SD of three independent experiments. P values were calculated using Student’s t test, *P < .05, **P < .01.
(B) Effect of WHSC1 siRNA knockdown on the viability of bladder and lung cancer cell lines. Relative cell number shows the value
normalized to siEGFP-treated cells. Results are the mean ± SD in three independent experiments. P values were calculated using Stu-
dent’s t test, *P < .05, **P < .01, ***P < .001. (C) Effect of siWHSC1 on cell cycle kinetics in A549 and SW780 cells. Cell cycle dis-
tribution was analyzed by flow cytometry after coupled staining with fluorescein isothiocyanate–conjugated anti-BrdU and 7-AAD as
described in Materials and Methods.
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both H3 and H4 histones in vitro [14,54]. A recent report showed that
the histone methyltransferase (HMT) activity of NSD proteins is sub-
strate specific, helping explain these discrepancies [55]. With regard to
carcinogenesis, key questions include the nature of the genes regulated
by WHSC1, the changes in chromatin that occur on such genes, and
the relevance of WHSC1 overexpression on each gene. In this study,
we demonstrate a mechanism involving regulation by WHSC1 through
methylation of histone H3-K36 occurring in human carcinogenesis.
β-Catenin is abundantly expressed in bladder and lung cancer
cell lines as well as the human colon cancer cell line HCT116
(Figure W6A) and that active-type β-catenin is also observed in the
nucleus of the lung cancer cell SBC5 and the bladder cancer cell
SW780 (FigureW6B). To elucidate the role of β-catenin in the growth
regulation of cancer cells, we performed knockdown experiments using
specific siRNA targeting β-catenin (FigureW6,C andD). The growth
rate of bladder and lung cancer cells was significantly suppressed after
knockdown of β-catenin, indicating that theWNT/β-catenin pathway
might play an important role in the growth regulation of these cells.
Because WHSC1 is overexpressed in various types of cancers like
pancreatic and breast cancers as well as bladder, lung, and colorectal
Figure 5.WHSC1 interacted with IQGAP1, TIAM1, and β-catenin. (A) WHSC1 isoform 2 (Figure W10, AAI52413) was used for this assay.
p3×FLAG-Mock and p3×FLAG-WHSC1 vectors were transfected into 293T cells. After 48 hours, interacting protein partners of WHSC1
were enriched by anti-FLAG immunoprecipitation, separated by SDS-PAGE, and silver stained. The different bands compared with a
control lane were cut out and identified by mass spectrometry. Western blot was performed to confirm the expression of FLAG-WHSC1
using anti-FLAG antibody. (B) Immunoprecipitates from lysates of 293T cells using anti-FLAG M2 agarose (Sigma-Aldrich) were
immunoblotted with anti-FLAG (WHSC1), IQGAP1, TIAM1, and β-catenin antibodies. (C) A 3×FLAG-WHSC1 (isoform 1; Figure W10,
NP_579877.1) vector was transfected into 293T cells, and cell lysates were immunoprecipitated with anti-FLAG M2 agarose (Sigma-
Aldrich). Immunoprecipitates were subjected to SDS-PAGE followed by Western blot analysis using a rabbit anti-FLAG antibody
(F7425; Sigma-Aldrich) and an anti–β-catenin antibody (610153; BD Biosciences). (D) The C-terminal region of WHSC1 directly interacts
with β-catenin but not GST. His-conjugated WHSC1 (residues 782-1365) and GST-conjugated full-length β-catenin were mixed in TBS
buffer (pH 7.6). After binding with TALON metal affinity resin (Clontech) for 1 hour, samples were washed three times with TBS buffer,
and boiled in sample buffer for subjecting to SDS-PAGE. Proteins were detected by CBB staining and Western blot analysis using anti-
GST (sc-138; Santa Cruz Biotechnology) and anti-His (631212; Clontech) antibodies. (E) Immunocytochemical analysis of WHSC1 and
β-catenin in HCT116 and SBC5 cells. Cells were stained with anti-WHSC1 (HPA015801; Sigma-Aldrich, Alexa Fluor 488 [green]), and
anti–active β-catenin antibodies (05-655; Millipore, Alexa Fluor 594 [red]) and DAPI (blue) (Figure W10).
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cancers, it is possible that the dysregulation of WNT/β-catenin path-
way we presented in this study may be observed in other cancers. In-
triguingly, flow cytometric cell cycle analysis revealed that knockdown
of WHSC1 reduced the cell population of cancer cells at the S phase
and increased that at the G2/M phase. Indeed, it is becoming ap-
parent that components of the WNT/β-catenin pathway, including
β-catenin, localize to the mitotic spindle or centrosomes and are in-
volved in the regulation of mitotic progression [56,57], indicating
that WHSC1might also regulate the M phase of cancer cells through
interactions with the WNT/β-catenin pathway.
We performed in vitromethyltransferase assays to test the possibil-
ity that β-catenin serves as a substrate of WHSC1-dependent meth-
ylation, but no positive signals were observed (data not shown).
Therefore, current data indicate that transcriptional regulation of
CCND1 by WHSC1 and β-catenin is solely due to the methylation
activity of WHSC1 on H3-K36 at the CCND1 promoter. In addi-
tion, immunocytochemical analysis showed that there are no ef-
fects of WHSC1 expression levels on the subcellular localization
of β-catenin (Figure W7). This implies that WHSC1 can regulate
the transcription together with β-catenin through methylation of
histone H3K36 in the nucleus but not affect the subcellular localiza-
tion of β-catenin. Furthermore, we have newly identified AKT2 as
an additional binding partner of WHSC1 (data not shown)—the
significance of this binding has not been elucidated yet. Further
Figure 6.WHSC1 regulates the WNT signaling pathway mediated by the epigenetic regulation of histone H3. (A) Left, signal intensity of
CCND1 in SW780 and A549 cells after treatment with siEGFP (control) and siWHSC1was quantified by GeneChip U133 plus 2.0 (Affymetrix).
Right, relative CCND1mRNA levels in A549 and SBC5 cells after treatment with siEGFP (control) and siWHSC1 were analyzed by quanti-
tative real-time PCR. mRNA expression levels were normalized by GAPDH and SDH expressions. Results are the mean ± SD in three in-
dependent experiments, and P values were calculated using Student’s t test, **P< .01. (B) ChIP assay for WHSC1wt andWHSC1ΔSET at
the promoter region of CCND1 gene. Top left, schematic diagram of the CCND1 promoter region. PCR-amplified fragments are positioned
by nucleotide number relatives to TSS (arrows). Bottom left, confirmation of WHSC1wt and WHSC1ΔSET protein expressions. The input
samples were fractionated by SDS-PAGE and immunoblotted with anti-FLAG antibody. The expression of ACTB was the internal control.
Middle, real-time PCR analysis using primer pairs as described under Materials and Methods. Cross-linked and sheared chromatin was
immunoprecipitatedwith anti-FLAG antibody (M2; Sigma-Aldrich). Protein A agarose/Salmon SpermDNA (Millipore) was used as a control.
The results are shown as a percentage of the input chromatin. Right, Quantification of H3K36triMe ChIP at the CCND1 promoter region
using real-time PCR. Cross-linked and sheared chromatinwas immunoprecipitatedwith anti-triMeH3K36 antibody (ab9050; Abcam, Cambridge,
United Kingdom). (C) TOPFLASHand FOPFLASHanalyses in 293T cells after transfectionwithmock,WHSC1wt, andWHSC1ΔSET vectors.
Themock vectorwas used as a control. Results are themean±SD in three independent experiments, and theP valuewas calculated using
Student’s t test, *P< .05, **P< .01. (D) Proposed model of WHSC1-mediated enhancement of β-catenin/TCF-4–dependent transcription
through histone H3 at lysine 36 trimethylation.
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functional analyses are needed to clarify the whole picture pertaining
to WHSC1 functions.
The SET domain containing protein NSD1 was reported to pro-
mote tumorigenesis in AML [53], and we report that expression levels
ofWHSC1 in various types of cancer are significantly higher than those
in corresponding nonneoplastic tissues. Expression profile analysis also
revealed overexpression of WHSC1L1 in various types of cancer, in-
cluding lung and bladder (data not shown). Therefore, we propose that
the abnormal expression of a family of methyltransferases (NSD1,
WHSC1, and WHSC1L1) may be linked to human carcinogenesis.
In particular, our expression data revealing that expression levels of
WHSC1 in normal tissues are significantly low (Figure W8) are in
agreement with the BioGPS database (Figure W9). Because of this,
WHSC1 may be a promising target for development of novel cancer
therapies. Recently, it has also been reported that deregulation of
WHSC1 is closely linked to human cancer [58–61], which reinforces the
potential of this protein as a therapeutic candidate. Because knockdown
of WHSC1 suppressed the growth of several cancer cells, this enzyme
seems to have a critical role in growth regulation of cancer cells. The data
imply that a specific and selective inhibitor for WHSC1 may be an ideal
candidate for molecular targeted cancer therapy. The development of
methyltransferase inhibitors has recently begun [62,63], and we antici-
pate that further studies may ensure the usefulness of this approach in the
near future.
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Table W1. Primer Sequences for Quantitative RT-PCR.
Gene Name Primer Sequence
GAPDH (housekeeping gene)-f 5′ GCAAATTCCATGGCACCGTC 3′
GAPDH (housekeeping gene)-r 5′ TCGCCCCACTTGATTTTGG 3′
SDH (housekeeping gene)-f 5′ TGGGAACAAGAGGGCATCTG 3′
SDH (housekeeping gene)-r 5′ CCACCACTGCATCAAATTCATG 3′
WHSC1-f1 5′ TCGAAGCAGCTCTTGTGTCTAAG 3′
WHSC1-r1 5′ TTTGGACCACACCAAATCACCAAC 3′
WHSC1-f2 5′ AATATGACTCCTTGCTGGAGCAGG 3′
WHSC1-r2 5′ ATTTCAACAGGTGGTCTTTGTCTC 3′
β-Catenin-f 5′ TGGTGGAATGCAAGCTTTAGG 3′
β-Catenin-r 5′ AAGGAGACCTTCCATCCCTTC 3′
Table W2. siRNA Sequences.
siRNA Name Sequence
siEGFP Sense: 5′ GCAGCACGACUUCUUCAAG 3′
Antisense: 5′ CUUGAAGAAGUCGUGCUGC 3′
siFFLuc Sense: 5′ GUGCGCUGCUGGUGCCAAC 3′
Antisense: 5′ GUUGGCACCAGCAGCGCAC 3′
siNegative control (Cocktail) Target #1 Sense: 5′ AUCCGCGCGAUAGUACGUA 3′
Antisense: 5′ UACGUACUAUCGCGCGGAU 3′
Target #2 Sense: 5′ UUACGCGUAGCGUAAUACG 3′
Antisense: 5′ CGUAUUACGCUACGCGUAA 3′
Target #3 Sense: 5′ UAUUCGCGCGUAUAGCGGU 3′
Antisense: 5′ ACCGCUAUACGCGCGAAUA 3′
siWHSC1#1 Sense: 5′ CAGAUCUACACAGCGGAUA 3′
Antisense: 5′ UAUCCGCUGUGUAGAUCUG 3′
siWHSC1#2 Sense: 5′ GUUAAUUGGCAUAUGGAAU 3′
Antisense: 5′ AUUCCAUAUGCCAAUUAAC 3′
siβ-catenin Sense: 5′ GAAUGAAGGUGUGGCGACA 3′
Antisense: 5′ UGUCGCCACACCUUCAUUC 3′
Table W3. Primer Sequences for Quantitative RT-PCR.
Primer Name Primer Sequence
CTNND1-Ch1-forward 5′ CAGTAACGTCACACGGACTAC 3′
CTNND1-Ch1-reverse 5′ CGCTCCCTCGCGCTCTTCTGC 3′
CTNND1-Ch2-forward 5′ CCCCTCTTCCCTGGCGGGGAG 3′
CTNND1-Ch2-reverse 5′ GCCCAAAAGCCATCCCTGAGG 3′
CTNND1-Ch3-forward 5′ GTGGTCTCCCCAGGCTGCGTG 3′
CTNND1-Ch3-reverse 5′ AGGGGTGCAGGGGGCCCCGTC 3′
CTNND1-Ch4-forward 5′ GCAGTCGCTGAGATTCTTTGG 3′
CTNND1-Ch4-reverse 5′ ACCACGAGAAGGGGTGACTGG 3′
CTNND1-Ch5-forward 5′ CGCCCCTGTGCGCCCGGAATG 3′
CTNND1-Ch5-reverse 5′ TCAGCGACTGCATCTTCTTTC 3′
CTNND1-Chn1-forward 5′ AAGCGGTTTCTGTGTGCGGTTCTG 3′
CTNND1-Chn1-reverse 5′ CTTTTCCCCTTTAAATGGGAGCAG 3′
CDK6-Ch1-forward 5′ GCCGCTGTGCCCACCCCCTCG 3′
CDK6-Ch1-reverse 5′ CTGAGGGGCCCAGTCGCGTCG 3′
Table W5. Gene Expression Profile ofWHSC1 in Cancer Tissues Analyzed by cDNAMicroarray*.
Tissue Type Case (n) Ratio (Tumor/Normal)
Count > 2 Count > 3 Count > 5 Count > 10
Bladder cancer 32 26 (81.3%) 18 (56.3%) 15 (46.9%) 3 (9.4%)
Breast cancer 40 31 (77.5%) 22 (55%) 8 (20%) 1 (2.5%)
Cholangiocellular carcinoma 15 6 (40%) 4 (26.7%) 1 (6.7%) 1 (6.7%)
CML 56 37 (66.1%) 27 (48.2%) 16 (28.6%) 10 (17.9%)
Esophageal cancer 18 9 (50%) 5 (27.8%) 3 (16.7%) 0 (0%)
HCC 14 8 (57.1%) 5 (35.7%) 5 (35.7%) 2 (14.3%)
NSCLC 28 10 (35.7%) 5 (17.9%) 2 (7.1%) 2 (7.1%)
SCLC 15 14 (93.3%) 12 (80%) 8 (53.3%) 1 (6.7%)
Osteosarcoma 16 9 (56.3%) 7 (35.7%) 4 (25%) 3 (18.8%)
Pancreatic cancer 13 12 (92.3%) 11 (84.6%) 10 (76.9%) 7 (53.8%)
Prostate cancer 38 18 (47.4%) 9 (23.7%) 5 (13.2%) 1 (2.6%)
Renal cell carcinoma 19 8 (42.1%) 5 (26.3%) 3 (13.2%) 0 (0%)
Soft tissue tumor 52 19 (36.5%) 10 (19.2%) 4 (7.7%) 2 (3.8%)
CML indicates chronic myelogenous leukemia; HCC, hepatocellular carcinoma.
*We compared the signal intensity of WHSC1 between tumor tissues and corresponding non-
neoplastic tissues derived from the same patient.
Table W4. Statistical Analysis of WHSC1 Expression Levels in Clinical Bladder Tissues.
Characteristic Case (n) WHSC1
Mean SD 95% CI
Normal (control) 22 0.219 0.086 0.183-0.254
Tumor (total) 120 0.527 0.681 0.406-0.649
Tumor stage
pTa, pT1 85 0.538 0.725 0.384-0.692
pT2 25 0.424 0.297 0.308-0.541
pT3, pT4 6 0.839 1.255 0-1.843
Tumor grade
G1 12 0.684 1.005 0.115-1.253
G2 60 0.495 0.715 0.314-0.676
G3 47 0.530 0.541 0.376-0.685
Metastasis
Negative 93 0.544 0.744 0.393-0.695
Positive 27 0.469 0.4 0.318-0.620
Gender
Male 88 0.505 0.562 0.388-0.623
Female 30 0.527 0.941 0.190-0.863
Recurrence
No 27 0.431 0.627 0.194-0.667
Yes 49 0.496 0.615 0.324-0.668
Died 8 1.014 1.691 0-2.186
Smoke
No 27 0.620 0.708 0.353-0.887
Yes 48 0.542 0.883 0.292-0.792
CI indicates confidence interval.
Figure W1. Validation of WHSC1 expression at the protein level. (A) Western blot analysis of one normal fibroblast cell (IMR-90) and
three cancer cell lines (ACC-LC-319, SBC5, and UMUC3) using an anti-WHSC1 antibody (HPA015801; Sigma-Aldrich). The expression of
ACTB served as an internal control. (B) Lysates from SBC5 cells after treatment with siEGFP (control) and siWHSC1 were immunoblotted
with an anti-WHSC1 antibody (HPA015801; Sigma-Aldrich). The expression of ACTB served as an internal control.
Figure W2. (A) Immunohistochemical staining ofWHSC1 in normal and cancer bladder tissues. Counterstainingwas donewith hematoxylin.
Originalmagnifications, ×100 and×400. (B) Tissuemicroarray images of lung tissues stained by standard immunohistochemistry for protein
expression ofWHSC1. Clinical information for each section is represented above histologic pictures. All tissue sampleswere purchased from
BioChain. Original magnification, ×400.
Table W6. Clinicopathologic Characteristics of Bladder Tissues on the Tissue Microarray*.
Case No. Age (years) Sex Histologic Diagnosis Grade Stage (TNM) WHSC1 Expression
1 71 M Normal — — −
2 59 M Normal — — −
3 65 M Chronic cystitis — — −
4 51 F Chronic cystitis — — −
5 71 M Squamous cell carcinoma 1 T1 N0 M0 ++
6 60 M Squamous cell carcinoma 1 T2 N0 M0 ++
7 76 M Adenocarcinoma 2 T2 N0 M0 ++
8 50 M Adenocarcinoma 2 T2 N0 M0 ++
9 68 M Adenocarcinoma 3 T2 N0 M0 ++
10 74 F Adenocarcinoma 3 T2 N0 M0 ++
11 27 M Transitional cell carcinoma 1 Tis N0 M0 +
12 50 M Transitional cell carcinoma 1 T1 N0 M0 −
13 49 F Transitional cell carcinoma 1 T1 N0 M0 +
14 67 M Transitional cell carcinoma 1 T1 N0 M0 +
15 51 F Transitional cell carcinoma 1 T1 N0 M0 ++
16 57 M Transitional cell carcinoma 1 T1 N0 M0 ++
17 47 M Transitional cell carcinoma 2 T2 N0 M0 ++
18 54 M Transitional cell carcinoma 2 T2 N0 M0 ++
19 45 M Transitional cell carcinoma 2 T1 N0 M0 ++
20 74 M Transitional cell carcinoma 2 T2 N0 M0 −
21 51 M Transitional cell carcinoma 2 T1 N0 M0 +
22 80 M Transitional cell carcinoma 2 T2 N0 M0 +
23 53 F Transitional cell carcinoma 2 T1 N0 M0 −
24 37 M Transitional cell carcinoma 2 T2 N0 M0 ++
25 55 M Transitional cell carcinoma 2 T4 N2 MX +
26 52 M Transitional cell carcinoma 2 T1 N0 M0 +
27 78 M Transitional cell carcinoma 3 T1 N0 M0 ++
28 64 M Transitional cell carcinoma 3 T3 N2 M1 ++
29 70 M Transitional cell carcinoma 3 T2 N0 M0 ++
30 61 M Transitional cell carcinoma 3 T2 N0 M0 +
31 61 M Transitional cell carcinoma 3 T1 N0 M0 ++
32 39 F Transitional cell carcinoma 3 T2 N0 M0 +
33 30 M Sarcoma — T2 N0 M0 ++
“−” indicates negative expression; “+,” low or moderate expression; “++,” high expression.
*All tissue samples were purchased from BioChain.
Table W7. Clinicopathologic Characteristics of Lung Tissues on the Tissue Microarray*.
Case No. Age (years) Sex Histologic Diagnosis Differentiation Stage (TNM) WHSC1 Expression
A1 29 F Human normal placenta −
A2 −
A3 60 M Pulmonary metastases renal cell carcinoma Moderately T2 Nx M1 +
A4 N/A N/A Adenocarcinoma T0 Nx Mx +
A5 N/A N/A Squamous cell carcinoma T0 Nx Mx −
A6 60 M Squamous cell carcinoma Poorly T2 N0 M0 −
A7 47 F Adenocarcinoma Poorly T2 N0 M0 −
A8 53 F Squamous cell carcinoma Moderately T0 N0 M0 +
A9 40 M Squamous cell carcinoma Moderately T2 N0 M0 +
A10 56 F Adenocarcinoma Poorly T2 N0 M0 ++
A11 49 M Squamous cell carcinoma Moderately T2 N0 M0 −
B1 45 F Bronchioalveolar carcinoma N/A T2 N0 M0 −
B2 34 F Fibrosarcoma Moderately T0 N0 M0 ++
B3 50 M Bronchioalveolar carcinoma N/A T3 N0 M0 +
B4 57 M Squamous cell carcinoma Poorly T2 N0 M0 ++
B5 65 M Atypical carcinoma (central type) Moderately T3 N0 M0 +
B6 36 F Adenocarcinoma, mucous Well T2 N0 M0 −
B7 57 M Squamous cell carcinoma Moderately T2 N0 M0 −
B8 29 M Squamous cell carcinoma Moderately T2 N0 M0 +
B9 52 M Undifferentiated small cell carcinoma Poorly T2 N0 M0 ++
B10 63 M Squamous cell carcinoma (cornifying) Moderately T3 N0 M0 +
B11 68 M Adenocarcinoma, papillary (peripheral type) Well T2 N1 M0 ++
C1 57 M Squamous cell carcinoma (center type) Well T2 N0 M0 ++
C2 56 F Tuberculosis N/A T1 N0 M0 −
C3 52 M Squamous cell carcinoma Moderately T2 N0 M0 +
C4 46 M Squamous cell carcinoma (cornifying) Well T3 N0 M0 +
C5 58 M Squamous cell carcinoma (central type) Moderately T2 N1 M0 ++
C6 63 M Adenocarcinoma Moderately T3 N0 M0 +
C7 61 F Bronchioalveolar carcinoma Well T2 N0 M0 +
C8 40 M Squamous cell carcinoma Well T3 N1 M0 ++
C9 64 M Squamous cell carcinoma Moderately T3 N0 M0 ++
C10 44 F Adenosqumous carcinoma Moderately T2 N1 M0 +
C11 61 M Squamous cell carcinoma Well T2 N0 M0 −
D1 65 F Squamous cell carcinoma Poorly T1 N0 M0 ++
D2 64 F Adenocarcinoma, papillary (peripheral type) Well T2 N0 M0 −
D3 70 M Adenosquamous carcinoma Moderately T2 N1 M0 ++
D4 68 M Undifferentiated small cell carcinoma Poorly T2 N0 M0 −
D5 65 M Carcinoma (peripheral type) Moderately T2 N0 M0 +
D6 59 F Adenocarcinoma, papillary Well T2 N0 M0 +
D7 67 M Squamous cell carcinoma Moderately T2 N0 M0 ++
D8 70 M Squamous cell carcinoma Poorly T2 N0 M0 ++
D9 47 F Adenocarcinoma Moderately T2 N0 M0 −
D10 71 M Squamous cell carcinoma Moderately T2 N0 M0 +
D11 65 M Squamous cell carcinoma Moderately T2 N0 M0 ++
E1 68 M Adenocarcinoma, squamous cell carcinoma Moderately T3 N0 M0 ++
E2 47 F Large cell Carcinoma Moderately T2 N0 M0 ++
E3 39 F Adenocarcinoma Moderately T2 N1 M0 −
E4 67 M Squamous cell carcinoma Moderately T2 N1 M0 −
E5 60 F Alveolus cell carcinoma N/A T2 N0 M0 +
E6 70 F Carcinoma Moderately T1 N0 M0 +
E7 27 M Sarcoma, metastasis tumor Moderately T2 Nx M1 +
E8 65 M Squamous cell carcinoma Moderately T3 N0 M0 +
E9 68 F Squamous cell carcinoma Moderately T2 N0 M0 +
E10 58 F Adenocarcinoma Moderately T2 N1 M0 −
E11 68 M Squamous cell carcinoma Well T2 N0 M0 +
F1 48 M Squamous cell carcinoma Moderately T3 N0 M0 −
F2 59 M Squamous cell carcinoma N/A T1 N0 M0 +
F3 54 M Adenocarcinoma, cyst Moderately T2 N1 M0 +
F4 45 M Squamous cell carcinoma Moderately T3 N0 M0 ++
F5 69 M Squamous cell carcinoma Poorly T2 N1 M0 ++
F6 78 F Alveolus cell adenocarcinoma Moderately T1 N0 M0 ++
F7 60 M Adenocarcinoma Moderately T1 N0 M0 +
F8 54 F Alveolus cell carcinoma Moderately T2 N1 M0 −
F9 78 M Alveolus cell carcinoma Moderately T1 N0 M0 −
F10 70 M Alveolus cell carcinoma Well T1 N0 M0 ++
F11 45 F Bronchioalveolar carcinoma Moderately T2 N0 M0 +
“−” indicates negative expression; “+,” low or moderate expression; “++,” high expression.
*All tissue samples were purchased from BioChain.








Negative (n = 48)
Sex
Male 231 124 107 NS (.8085)
Female 97 50 47
Age (years)
<65 146 77 69 NS (>.9999)
≧65 182 97 85
Histologic type
ADC 195 98 97
SCC 99 55 44 NS (.2599*)
Others* 34 21 13
Smoking status
Never 92 49 43 NS (>.9999)
Smoker 236 125 111
pT factor
T1 136 75 61 NS (.5748)
T2 + T3 192 99 93
pN factor
N0 216 109 107 NS (.2015)
N1 + N2 112 65 47
ADC indicates adenocarcinoma; NS, no significance; Others, large cell carcinoma plus adeno-
squamous cell carcinoma; SCC, squamous cell carcinoma.
*ADC versus non-ADC.
Figure W3. No correlation between WHSC1 expression and the
prognosis of lung cancer. Kaplan-Meier estimates of overall survival
time of patients with NSCLC (P = .8629, log-rank test).
Table W9. Cox Proportional Hazards Model: Analysis of Prognostic Factors in Patients with NSCLCs.
Variables Hazards Ratio 95% CI Unfavorable/Favorable P
Univariate analysis
WHSC1 0.971 0.694-1.358 Positive/negative NS (.8629)
Age (years) 1.863 1.304-2.661 65≧/<65 .0006*
Sex 1.634 1.100-2.427 Male/female .0149*
Histologic type 1.548 1.108-2.162 Non-ADC/ADC .0104*
Smoking status 1.312 0.887-1.941 Smoker/never NS (.1738)
pT factor 2.421 1.647-3.559 T2 + T3/T1 <.0001*
pN factor 3.268 2.309-4.608 N1 + N2/N0 <.0001*
Multivariate analysis
Age (years) 2.091 1.454-3.007 65≧/<65 <.0001*
Sex 1.294 0.833-2.012 Male/female NS (.2519)
Histologic type 0.935 0.642-1.361 Non-ADC/ADC NS (.7247)
pT factor 1.838 1.220-2.770 T2 + T3/T1 .0036*
pN factor 2.227 1.572-3.155 N1 + N2/N0 <.0001*
*P < .05.
Table W10. Gene Ontology Pathway Analysis of WHSC1 Based on the Affymetrix’s Microarray Data.
Entry ID Name Definition P
GO0006261 DNA-dependent DNA replication The process whereby new strands of DNA are synthesized, using parental
DNA as a template for the DNA-dependent DNA polymerases that
synthesize the new strands.
1.75 × 10−4
GO0007254 JNK cascade A cascade of protein kinase activities, culminating in the phosphorylation
and activation of amember of the JUN kinase subfamily of stress-activated
protein kinases, which in turn are a subfamily ofmitogen-activated protein
(MAP) kinases that is activated primarily by cytokines and exposure to
environmental stress.
5.28 × 10−4
GO0043506 Regulation of JNK activity Any process that modulates the frequency, rate, or extent of JUN
kinase activity.
9.44 × 10−4
GO0000165 MAPKKK cascade Cascade of at least three protein kinase activities culminating in the
phosphorylation and activation of a MAP kinase.
3.29 × 10−3
GO0006268 DNA unwinding during replication The process by which interchain hydrogen bonds between two strands
of DNA are broken or “melted,” generating unpaired template strands
for DNA replication.
3.80 × 10−3
GO0032508 DNA duplex unwinding The process by which interchain hydrogen bonds between two strands
of DNA are broken or “melted,” generating a region of unpaired
single strands.
5.19 × 10−3
GO0006270 DNA replication initiation The process by which DNA replication is started; this involves the
separation of a stretch of the DNA double helix, the recruitment
of DNA polymerases, and the initiation of polymerase action.
7.64 × 10−3
GO0017147 Wnt protein binding Interacting selectively with Wnt protein, a secreted growth factor
involved in signaling.
9.27 × 10−3
GO0000187 Activation of MAPK activity The process of formation of a ring composed of actin, myosin, and
associated proteins that will function in cytokinesis.
1.10 × 10−2
GO0006260 DNA replication The process whereby new strands of DNA are synthesized. The template
for replication can be either an existing DNA molecule or RNA.
1.44 × 10−2
GO0022402 Cell cycle process A cellular process that is involved in the progression of biochemical and
morphologic phases and events that occur in a cell during successive
cell replication or nuclear replication events.
1.99 × 10−2
GO0022616 DNA strand elongation The DNA metabolic process by which a DNA strand is synthesized by
adding nucleotides to the 3′ end of an existing DNA stand.
2.33 × 10−2
GO0042813 Wnt receptor activity Combining with a member of the Wnt family of signaling molecules to
initiate a change in cell activity.
2.45 × 10−2
Figure W4. Elevated expression of WHSC1 in colon cancer. (A) Expression ofWHSC1 in one normal cell line and three colon cancer cell
lines analyzed by quantitative real-time PCR. mRNA expression levels were normalized by GAPDH, and values are relative to IMR-90.
(B) Immunohistochemical staining of WHSC1 in colorectal tissues. Clinical information for each section is represented above histologic
pictures. Tissue samples were purchased from BioChain. Original magnification, ×400. (C) Positive ratio of WHSC1 protein in CRC
tissues analyzed by tissue microarray.
Figure W5. ChIP assay for WHSC1wt and WHSC1ΔSET. (A) Schematic diagram of the CCND1 and CDK6 promoter region. PCR-amplified
fragments are positioned by nucleotide number relatives to TSS (arrows). The Chn1 region is located at 5-kbp upstream from TSS of the
CDK6 gene. (B) Real-time PCR analysis using primer pairs as described under Materials andMethods. Cross-linked and sheared chromatin
was immunoprecipitatedwith anti-FLAG antibody (M2; Sigma). The results are shown as the relative value calculated as follows: percentage
of the input chromatinof eachFLAGprecipitant / percentageof the input chromatinof thecorrespondingcontrol precipitant. (C)Quantification
of H3K36triMe ChIP at the CCND1 and CDK6 promoter regions using real-time PCR. Cross-linked and sheared chromatin was immuno-
precipitated with anti-triMeH3K36 antibody (ab9050; Abcam).
Figure W6. Knockdown of β-catenin suppresses the growth of bladder and lung cancer cells. (A) Expression levels of β-catenin in HCT116,
A549, SBC5, and SW780 cells analyzed by quantitative real-time PCR. mRNA expression levels were normalized by GAPDH and SDH ex-
pressions, and values are relative to HCT116 (HCT116 = 1). (B) Immunocytochemical analysis of SBC5 and SW780 cells stained with an
anti–active β-catenin antibody (05-655; Alexa Fluor 594 [red]) and DAPI (blue). (C) Quantitative real-time PCR showing suppression of en-
dogenous expression of β -catenin after treatment with specific siRNA in A549 cells. siEGFP and siNC were used as controls. mRNA ex-
pression levels were normalized by GAPDH and SDH expressions, and values are relative to siEGFP (siEGFP = 1). (D) Effects of β-catenin
knockdown on the viability of bladder and lung cancer cell lines. Relative cell number shows the value normalized to siEGFP-treated cells.
Results are the mean ± SD in three independent experiments. P values were calculated using Student’s t test, *P < .05.
Figure W7. Effects of WHSC1 expression on the subcellular localization of β-catenin. HCT116 cells were transfected with a WHSC1
expression vector, and immunocytochemical analysis was conducted using an anti-WHSC1 antibody (HPA015801) and an anti–active
β-catenin antibody (05-655). DAPI was used to stain the nucleus.
Figure W8. Expression levels ofWHSC1 in 29 normal tissues. Signal intensity was quantified by cDNA microarray described in Materials
and Methods. GAPDH expression is shown as a control of the signal intensity.
Figure W9. Expression levels ofWHSC1 in 78 normal tissues. Data were derived from BioGPS (http://biogps.gnf.org/#goto=welcome).
GAPDH expression is shown as a control of the signal intensity.
Figure W10. Structure of WHSC1 analyzed by SMART (Simple Modular Architecture Research Tool). National Center for Biotechnology
Information Reference Sequence: NP_579877.1 (1365 aa, WHSC1 isoform 1), AAI52413 (713 aa, WHSC1 isoform 2).
